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OBJECTIVES The goal of this study was to evaluate platelet function and to preliminarily assess the clinical
safety of sequential treatment with tirofiban or eptifibatide followed by abciximab in patients
undergoing percutaneous coronary intervention (PCI).
BACKGROUND An increasing number of acute coronary syndrome (ACS) patients are treated early with
tirofiban or eptifibatide. Some later require PCI and may benefit from switching to
abciximab, for which long-term benefits have been reported.
METHODS Fifty ACS patients planned for PCI were enrolled. Twenty-five patients received tirofiban
followed by abciximab. Ten patients received eptifibatide followed by abciximab. Fifteen
patients received only abciximab. All patients had blood samples drawn six times during the
therapeutic course. Platelet function was evaluated by ADP- and TRAP-induced aggrega-
tion, flow cytometry analysis of fibrinogen binding and the cone and plate(let) analyzer, which
tests shear rate-dependent platelet activation.
RESULTS Administered after tirofiban, abciximab caused a significant further decline in platelet
function, as evidenced by all methods. Administered after eptifibatide, abciximab caused a
significant further reduction in platelet function, as assessed by the cone and plate(let)
analyzer and fibrinogen binding methods. The platelet inhibition achieved by the combina-
tion therapy was always greater than or equal to that achieved by abciximab alone. There were
no major bleeding or severe thrombocytopenia episodes. Three of the 35 combination therapy
patients and one of the 15 who received abciximab alone had minor bleeding.
CONCLUSIONS This is the first in vivo study of combination intravenous platelet glycoprotein IIb/IIIa
inhibitor therapy. Administration of abciximab immediately after tirofiban or eptifibatide
therapy effectively inhibits platelet function and appears to be safe. (J Am Coll Cardiol 2001;
37:847–55) © 2001 by the American College of Cardiology
Platelets play a fundamental role in the pathogenesis of
acute coronary syndromes (ACS) and the development of
ischemic events complicating percutaneous coronary inter-
vention (PCI) (1,2). The development of inhibitors of
platelet glycoprotein (GP) IIb/IIIa, which block the com-
mon final pathway leading to platelet aggregation, has
extended the therapeutic options for reducing ischemic
complications. To date, three GPIIb/IIIa inhibitors have
been approved by the U.S. Food and Drug Administration:
the chimeric (murine/human) monoclonal antibody (c7E3
Fab) abciximab (ReoPro), the nonpeptide tyrosine deriva-
tive tirofiban (Aggrastat) and the cyclic heptapeptide epti-
fibatide (Integrilin). Six large placebo-controlled, double-
blind trials using GPIIb/IIIa inhibitors in patients
undergoing PCI have shown that all three agents reduce the
rate of acute ischemic complications (3–8). However, only
abciximab has been shown to improve long-term outcomes
of PCI (9–11). Specifically, the significant reductions in
death, in myocardial infarction (MI) and in the need for
urgent revascularization conferred by abciximab were still
present one to three years after the PCI (9–11).
Following the PRISM-PLUS and PURSUIT trials
(12,13), there has been an increasing usage of tirofiban and
eptifibatide to treat ACS patients in the early phase of their
clinical course. Some of these patients later require PCI and
may benefit from the long-term improvement in outcomes
that had been documented with abciximab (9–11). The
question therefore arises: can abciximab be administered
effectively and safely to patients who arrive at the catheter-
ization lab treated with the short-acting inhibitors, tirofiban
or eptifibatide?
Small molecule GPIIb/IIIa inhibitors, such as tirofiban,
can cause conformational changes within the GPIIb/IIIa
complex and induce the formation of novel epitopes (14).
These conformational changes may interfere with subse-
quent binding of abciximab to the GPIIb/IIIa receptor.
However, in vitro studies have demonstrated that abciximab
binding to platelets is not adversely affected by prior
exposure to tirofiban (15). Moreover, abciximab has a
substantially higher affinity for the GPIIb/IIIa receptor than
tirofiban or eptifibatide (16). Thus, we hypothesized that
the presence of a small molecule GPIIb/IIIa inhibitor would
not impede the inhibitory effect of abciximab on platelet
function.
The aim of this study was to evaluate platelet function
using various methods and to preliminarily assess the
clinical safety of sequential treatment with tirofiban or
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eptifibatide followed by abciximab with a short overlap in
ACS patients undergoing PCI.
METHODS
Patients. Patients (n 5 50) were eligible for the study if
they had an ACS, defined as unstable angina at presenta-
tion, or an acute MI within the previous two weeks. All
patients were scheduled to undergo PCI within 24 h of
enrollment. Exclusion criteria included an acute MI within
48 h, history of hemorrhagic diathesis, any major surgery,
gastrointestinal or genitourinary bleeding within six weeks,
history of stroke within two years or a residual neurological
deficit, concurrent administration of oral anticoagulants
unless the prothrombin time was #1.2 times control,
thrombocytopenia (,100,000 cells/ml), hemoglobin level
,12 gm/dl, severe uncontrolled hypertension or use of a
thrombolytic agent within 48 h. This study was approved by
the institutional review board of the Mount Sinai Hospital,
and informed consent was obtained from each patient. The
study was performed from March to October 1999.
Study medications. The study was comprised of three
patient groups. Group I consisted of 25 consecutive patients
who received tirofiban followed by abciximab (tirofiban-
abciximab group). Group II consisted of 10 consecutive
patients who received eptifibatide followed by abciximab
(eptifibatide-abciximab group). Group III consisted of 15
consecutive patients who served as controls and received
only abciximab (abciximab control group). All patients
received concomitant therapy with aspirin 325 mg orally
daily, except for two who received clopidogrel because of
aspirin allergy. All patients were given initial therapy with
heparin—a bolus of 50 U/kg intravenously and an infusion
of 7 U/kg—adjusted to achieve 1.3 to 1.5 times the control
APTT value. Heparin was continued until about an hour
before the PCI.
In the tirofiban-abciximab group, tirofiban (gift from
Merck & Co. Inc. West Point, Pennsylvania) was admin-
istered with heparin as an intravenous bolus of 0.4 mg/kg/
min for 30 min, followed by 0.1mg/kg/min infusion over 20
to 24 h (12). In the eptifibatide-abciximab group, eptifi-
batide (gift from COR Therapeutics, Inc., San Francisco,
California) was administered with heparin as an intravenous
bolus of 180 mg/kg (pushed), followed by 2.0 mg/kg/min
infusion over 20 to 24 h (13). In the abciximab control
group, no GPIIb/IIIa inhibitor was given with heparin
before the patient’s arrival at the catheterization lab.
Just before the PCI, after obtaining arterial access, abcix-
imab was initiated in all patients with the tirofiban or
eptifibatide infusions still maintained in the first two groups.
Abciximab was administered at 0.25 mg/kg bolus intrave-
nously (pushed), followed immediately by 0.125 mg/kg/min
infusion administered continuously over 12 h. Tirofiban or
eptifibatide were discontinued after 5 min of overlap with
the abciximab infusion. After their discontinuation, heparin
was administered at a bolus of 30 U/kg followed by
additional boluses of 10 U/kg as necessary to maintain an
activated clotting time $200 s. Heparin was not adminis-
tered after PCI. Patients having stent deployment received
clopidogrel 75 mg orally once daily for four weeks.
Blood samples. Blood was collected from the tirofiban-
abciximab group and 10 patients of the abciximab control
group in vacutainers containing 3.8% sodium citrate. The
eptifibatide-abciximab patients and five patients of the
abciximab control had blood collected in vacutainers con-
taining D-Phe-Pro-Arg chloromethyl ketone dihydrochlo-
ride (PPACK) (17). In both combination therapy groups,
six samples were taken: 1) at baseline (on aspirin and
heparin therapy); 2) after the tirofiban or eptifibatide bolus;
3) on steady-state tirofiban or eptifibatide infusion, just
before the abciximab bolus; 4) at the end of the 5-min
overlap period, just before the discontinuation of tirofiban
or eptifibatide; 5) at 4 h after the initiation of abciximab;
and 6) at 10 to 12 h after the discontinuation of abciximab.
The abciximab control patients had blood samples drawn at
parallel times, with sample 4 taken 5 min after abciximab
initiation. In all patients, samples 1, 2, 5 and 6 were drawn
from the antecubital vein by venipuncture using a 21-gauge
needle, and samples 3 and 4 were drawn from a 7Fr arterial
access sheath.
Assessment of platelet function. PLATELET AGGREGA-
TION. Turbidimetric platelet aggregation was performed in
platelet rich plasma (PRP) in response to 20 mM ADP and
15 mM of thrombin receptor activating peptide (TRAP), as
previously described (18). The extent of aggregation was
defined as the maximal amount of light transmission
reached within 6 min after addition of the agonist.
CONE AND PLATE(LET) ANALYZER (CPA). The CPA test
quantifies platelet deposition under flow conditions. In this
test, anticoagulated whole blood is placed in polystyrene
wells and circulated at high shear rate (1,300 s21) with a
rotating cone (19). The wells are then washed with PBS,
stained with May-Gru¨nwald stain and analyzed with an
inverted light microscope connected to an image analysis
system (19). The results were expressed as the percentage of
total surface covered by platelets.
FLOW CYTOMETRY ANALYSIS OF FIBRINOGEN BINDING. As
previously described (20), platelet activation was quantified
by flow cytometric analysis of fibrinogen binding. This assay
Abbreviations and Acronyms
ACS 5 acute coronary syndrome
CPA 5 cone and plate(let) analyzer
GP 5 platelet glycoprotein
MI 5 myocardial infarction
NS 5 nonsignificant
PCI 5 percutaneous coronary intervention
PPACK 5 D-Phe-Pro-Arg chloromethyl ketone
dihydrochloride
PRP 5 platelet rich plasma
TRAP 5 thrombin receptor activating peptide
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(Wak-Chemie Medical GMBH, Germany) incorporates
FITC-conjugated chicken antifibrinogen antibody, PRP,
HEPES buffer or HEPES-EDTA for the negative control
and stimulation by 0.6 mM ADP. Samples were analyzed in
a FACSCalibur (Becton-Dickenson) and were gated on
log-forward versus log-side scatter to identify the platelet
population. Platelets with fluorescence greater than a
marker set according to the negative controls were identified
as positive events. Results of platelet function in all three
assays were expressed as percentage of baseline.
GPIIb/IIIa receptor binding assay. This method was
applied to four patients in each of the three groups. The
method uses a flow cytometric assay to quantify binding of
two monoclonal antibodies LYP18 (Mab1) and 4F8
(Mab2) to GPIIb/IIIa receptors (21). Binding of Mab1 to
GPIIb/IIIa receptors has been shown to be inhibited by
abciximab, whereas Mab2 binding is unaffected by it. In
contrast, small molecular weight antagonists inhibit Mab2,
but not Mab1, binding (21). We used the platelet GPIIb/
IIIa occupancy kit (Biocytex, France) to determine Mab1
and Mab2 binding in our study groups. This kit employs
whole blood diluted 1:4 in PBS BSA buffer, a negative
isotypic control, Mab1 reagent, Mab2 reagent, a calibrated
bead suspension and a polyclonal antibody antimouse IgG-
FITC. Samples were analyzed in a FACSCalibur (Becton-
Dickenson) and gated on log-forward versus log-side scatter
to identify the platelet or beads populations. A calibration
curve was plotted using the mean fluorescence intensity of
the beads and their corresponding number of monoclonal
antibody molecules. Results were expressed as the total
number of binding sites for Mab1or Mab2 per platelet.
Assessment of safety. Complete blood count was taken at
all six time points and before the patient’s discharge.
Bleeding was defined according to the criteria used by the
Thrombolysis in Myocardial Infarction (TIMI) trial (22).
Severe thrombocytopenia was defined by a nadir platelet
count below 50,000/ml. Mild thrombocytopenia was de-
fined as a platelet count below 100,000/ml or a nadir below
50% of the baseline value.
Statistical analysis. Patient demographics and platelet
function data were described using mean 6 SEM. Platelet
function results were analyzed using a two-way analysis of
variance with repeated measures between the different
groups (between-subject factor) and time points (within-
subject factor). Analysis of variance was performed sepa-
rately for each combination therapy group and its corre-
sponding abciximab control group. Categorical variables
were compared using the Fisher exact test. Analyses were
performed using SPSS version 10 statistical software, and
statistical significance was considered as p , 0.05.
RESULTS
Patient demographics. A total of 50 patients representing
a typical population undergoing PCI were treated. Their
baseline characteristics are outlined in Table 1. There were
no significant differences in any of the parameters between
the three groups. All coronary interventions were successful
(,50% residual stenosis). Forty-six patients (92%) had
stents placed in the target vessel, and four patients (8%)
underwent balloon angioplasty.
Safety outcomes. There were no major bleeding episodes
in any of the groups. Two patients in the tirofiban-
abciximab group and one each in the eptifibatide-abciximab
and abciximab control groups had minor bleeding (p 5
NS). No blood transfusions were required. In addition, five
patients in the tirofiban-abciximab group and one each in
the eptifibatide-abciximab and the abciximab control groups
had episodes of mild mucocutaneous bleeding, which did
not qualify as minor bleeding. There were no episodes of
severe thrombocytopenia. One patient in the tirofiban-
abciximab group, none in the eptifibatide-abciximab group
and two in the abciximab control group had mild thrombo-
cytopenia.
Tirofiban-abciximab platelet function assays. The 25
patients in the tirofiban-abciximab group were compared
with 10 patients from the abciximab control group using
citrate as the anticoagulant. Overall analysis of variance was
significant for the time effect (p , 0.0001) and interaction
term (p , 0.0001) for all platelet function assays used. The
residual platelet aggregation in response to 20 mM ADP is
shown in Figure 1. Platelet aggregation decreased from
baseline (100%) after the tirofiban bolus, was not signifi-
cantly changed during the tirofiban infusion, and decreased
Table 1. Patient Demographics
Tirofiban-
Abciximab
(n 5 25)
Eptifibatide-
Abciximab
(n 5 10)
Abciximab
Control
(n 5 15)
Age 57.8 6 1.8 59.1 6 3.8 60 6 3.9
Men, n (%) 20 (80) 9 (90) 9 (60)
Diabetes, n (%) 6 (24) 4 (40) 5 (33.3)
Hyperlipidemia, n (%) 13 (52) 7 (70) 11 (73.3)
Smoking, n (%) 12 (48) 5 (50) 5 (33.3)
Unstable angina, n (%) 19 (76) 9 (90) 13 (86.6)
Myocardial infarction, n (%) 6 (24) 1 (10) 2 (13.3)
Baseline platelets (1,000/ml) 257.8 6 22.1 205.3 6 17.9 232.36 6 15.6
Baseline hemoglobin (gm/dl) 13.68 6 0.2 13.98 6 0.4 12.75 6 0.6
Data presented as mean 6 SEM or number (percentage) of patients.
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further after the abciximab bolus (decrease from 12.4 6
3.4% during tirofiban maintenance to 2.6 6 1% after
abciximab [p , 0.003]). Platelet aggregation in response to
15 mM TRAP showed a similar trend but with higher
residual values (aggregation of 35.9 6 5.3% after the
tirofiban bolus and a decrease from 33.4 6 4.2% during
tirofiban maintenance to 16.7 6 2.3% after abciximab [p ,
0.0001]).
The residual fibrinogen binding results in the tirofiban-
abciximab and abciximab control groups are shown in
Figure 1. The differences between the tirofiban bolus and
maintenance points were nonsignificant. After the abcix-
imab bolus, fibrinogen binding decreased significantly (from
25.6 6 4.3% to 5.2 6 1.9% [p , 0.0001]). Cone and
plate(let) analyzer results showed a similar trend (platelet
coverage of 19.3 6 2.9% after the tirofiban bolus and a
decrease from 23.6 6 4.5% during tirofiban maintenance to
2.2 6 0.8% after abciximab [p , 0.0001]). Cone and
plate(let) analyzer photomicrographs of a representative
patient are shown in Figure 2.
A comparison between the tirofiban-abciximab and ab-
ciximab control groups revealed that residual platelet func-
tion at the post-abciximab bolus point was always lower in
the tirofiban-abciximab group; however, the difference was
significant only for 20 mM ADP aggregation (p , 0.02) and
not the other platelet assays.
Figure 1. Residual platelet function assessed by 20 mM ADP-induced aggregation (top) and flow cytometry analysis of fibrinogen-platelet binding (bottom)
in 25 patients who received tirofiban followed by abciximab and in 10 patients who received only abciximab. Results are expressed as mean 6 SEM percent
of baseline aggregation. Administration of abciximab to tirofiban-treated patients caused a significant decrease in platelet function. Open square 5
tirofiban-abciximab group; solid circle 5 abciximab control group. Abx 5 abciximab; Maint 5 maintenance; Tir 5 tirofiban.
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Eptifibatide-abciximab platelet function assays. The 10
patients in the eptifibatide-abciximab group were compared
with five patients from the abciximab control group using
PPACK as the anticoagulant. Overall analysis of variance
was significant for the time effect (p , 0.0001) and
interaction term (p , 0.0005) for all platelet function assays
used. The residual platelet aggregation in response to
20 mM ADP is shown in Figure 3. Platelet aggregation
decreased from baseline (100%) after the eptifibatide bolus
and was not significantly changed during the eptifibatide
infusion or after the abciximab bolus (2.8 6 1.1% during
eptifibatide maintenance and 1.2 6 0.8 after the abciximab
bolus [p 5 NS]). Platelet aggregation in response to 15 mM
TRAP showed a similar trend but with higher residual
values (aggregation of 17.5 6 5.2% after the eptifibatide
bolus and a decrease from 13 6 4.5% during the eptifibatide
maintenance to 6.1 6 4.1% after the abciximab bolus [p 5
NS]).
The residual fibrinogen binding results in the
eptifibatide-abciximab and abciximab control groups are
shown in Figure 3. The differences between the eptifibatide
bolus and maintenance points were nonsignificant. After the
abciximab bolus, fibrinogen binding decreased significantly
(from 17.2 6 3% to 6.6 6 3.1 [p , 0.008]). Cone and
plate(let) analyzer results showed a similar trend (platelet
coverage of 25 6 3.8% after the eptifibatide bolus and a
decrease from 21.3 6 3.1% during eptifibatide maintenance
to 1.9 6 0.4% after abciximab [p , 0.001]).
A comparison between the eptifibatide-abciximab and
abciximab control groups revealed that residual platelet
function at the post-abciximab bolus point was always lower
in the eptifibatide-abciximab group; however, the difference
was not significant for any of the platelet function assays.
GPIIb/IIIa receptor binding. The mean number of Mab1
and Mab2 binding sites per platelet in the tirofiban-
abciximab and eptifibatide-abciximab groups is displayed in
Figure 4. After the tirofiban bolus and maintenance, the
number of Mab2 sites decreased to 32.4% and 29.7% of the
baseline value, respectively, whereas the number of Mab1
sites did not change significantly. The abciximab bolus
caused an increase in Mab2 sites to 75.8% and a concurrent
marked decrease in Mab1 to 9% of baseline. Eptifibatide
had a similar effect. After the eptifibatide bolus and main-
tenance, the number of Mab2 binding sites decreased to
30.9% and 26.3% of baseline, respectively, whereas the
number of Mab1 sites did not change significantly. The
abciximab bolus again caused an increase in Mab2 sites to
99.6% and a concurrent marked decrease in Mab1 to 4.8%
of baseline.
DISCUSSION
This is the first in vivo study of combination intravenous
GPIIb/IIIa inhibitor therapy. Previously, only sequential
parenteral-oral GPIIb/IIIa blockade therapy has been ex-
amined and was found to be synergistic in its pharmacody-
namic effect (23). By assessing various aspects of platelet
function—aggregation, fibrinogen binding and high shear
rate-induced surface deposition—we demonstrated that ef-
fective and continuous platelet inhibition is achieved when
full dose abciximab is administered to patients already
receiving full dose tirofiban or eptifibatide. Platelet inhibi-
tion after the abciximab bolus, at the point when both drugs
were given simultaneously, was consistently equal to or
greater than that achieved by any of the three agents alone.
The study did not aim to compare the effects of the three
GPIIb/IIIa inhibitors on platelet function. It was divided
into two cohorts: tirofiban-abciximab and eptifibatide-
abciximab, each with its own abciximab control group and
anticoagulant. Citrate, as opposed to PPACK, has been
shown to have a calcium-depleting effect with subsequent
overestimation of platelet inhibition by eptifibatide (17).
Thus, PPACK was used as the anticoagulant in the
eptifibatide-abciximab cohort, while citrate was used for the
tirofiban-abciximab cohort, to enable comparison to previ-
ous studies.
In all treatment groups, the highest residual platelet
function values were generally achieved by platelet aggrega-
tion with 15 mM TRAP. These findings are consistent with
previous reports of .60% residual 15 mM TRAP induced
aggregation 2 h after an abciximab bolus (24). Stimulation
of platelets with thrombin has been shown to cause up to a
50% increase in the number of GPIIb/IIIa receptors avail-
able on the platelet surface, through recruitment of recep-
Figure 2. Photomicrographs of the cone and platelet analyzer results in a representative tirofiban-abciximab patient. This method assesses platelet
deposition at a high shear rate, and the results are expressed as the percentage of total surface covered by platelets. Micrograph (A) was taken at baseline
(12.1% coverage), (B) after tirofiban bolus (2.2% coverage) and (C) after abciximab bolus, when tirofiban was still being infused (0.1% coverage). All
micrographs were taken at magnification 310.
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tors from a-granules to the plasma membrane (25). This
process may explain the increased platelet reactivity we have
found in response to TRAP.
Tirofiban-abciximab group. The residual platelet function
after tirofiban administration ranged from 12% to 26%
when assessed by all platelet assays, except for 15 mM
TRAP aggregation. These findings are consistent with a
recent study that also assessed platelet function after tirofi-
ban therapy (26). Administration of abciximab to the
patients treated with tirofiban caused a further reduction in
platelet function. Moreover, residual platelet aggregation
after the abciximab bolus was lower than that achieved by
abciximab alone in the abciximab control group. These
findings are supported by previous in vitro data (15) and by
the results of the GPIIb/IIIa receptor binding assay in our
study. Both demonstrated that binding of abciximab to the
GPIIb/IIIa receptor is not adversely affected by the presence
of tirofiban.
Eptifibatide-abciximab group. Administration of abcix-
imab after eptifibatide caused only minor nonsignificant
declines in platelet aggregation. This is probably because
aggregation was already markedly inhibited during the
Figure 3. Residual platelet function assessed by 20 mM ADP induced aggregation (top) and flow cytometry analysis of fibrinogen-platelet binding (bottom)
in 10 patients who received eptifibatide followed by abciximab and in five patients who received only abciximab. Results are expressed as mean 6 SEM
percent of baseline aggregation. A significant decrease in platelet function after the abciximab bolus was evidenced only by the fibrinogen-binding assay.
Open square 5 eptifibatide-abciximab group; solid circle 5 abciximab control group. Abx 5 abciximab; Ept 5 eptifibatide; Maint 5 maintenance.
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eptifibatide infusion (2.8% residual aggregation with 20 mM
ADP), as previously reported (26). Therefore, only a limited
further decline was achieved by the addition of abciximab.
In contrast, both the fibrinogen binding and CPA assays
showed significant decreases after the abciximab bolus. Our
data, therefore, suggest that analysis of fibrinogen binding
to activated platelets and quantification of platelet deposi-
tion under flow conditions may be more sensitive methods
than aggregation for the detection of platelet function
changes at high levels of GPIIb/IIIa receptor inhibition.
This hypothesis is supported by previous findings that
platelet aggregation is only minimally affected at receptor
occupancy levels of ,30% and .80% (27).
GPIIb/IIIa receptor binding. In both combination ther-
apy groups, the abciximab bolus, administered when tirofi-
ban or eptifibatide were still infusing, had a similar effect on
binding of the monoclonal antibodies Mab1 and Mab2. As
expected, the number of available Mab1 binding sites
decreased markedly, indicating that prior treatment with
tirofiban or eptifibatide does not interfere with binding of
abciximab to the GPIIb/IIIa receptor. Surprisingly, at the
same time, the number of available Mab2 sites increased
Figure 4. Binding of the monoclonal antibodies Mab1 and Mab2 to glycoprotein IIb/IIIa receptors on platelets. Mab1 is displaced by abciximab, whereas
Mab2 is displaced by small molecule glycoprotein IIb/IIIa inhibitors. Results are expressed as mean 6 SEM binding sites per platelet in four patients from
the tirofiban-abciximab group (top) and four patients from the eptifibatide-abciximab group (bottom). The abciximab bolus caused a marked decrease in
Mab1 binding and a concurrent increase in Mab2 binding in both groups. Open square 5 Mab1; solid circle 5 Mab2. Abx 5 abciximab; Ept 5
eptifibatide; Maint 5 maintenance; Tir 5 tirofiban.
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considerably, suggesting that the addition of abciximab may
have resulted in displacement of tirofiban or eptifibatide
from their binding site in the receptor. This displacement
seems to be more complete with eptifibatide (increase in
Mab2 to 99.6% of baseline) than with tirofiban (increase to
75.8% of baseline). This is in accordance with the dissoci-
ation constants of abciximab, tirofiban and eptifibatide,
which are 5, 15 and 120 nmol/L, respectively (16).
Safety outcomes. Of a total of 35 patients who received a
small molecule GPIIb/IIIa inhibitor followed immediately
by abciximab, three (8.6%) developed minor bleeding com-
plications, and none developed major bleeding complica-
tions. This bleeding complication rate is similar to that of
the abciximab control group (6.7%). It is also within the
range of the major and minor bleeding complications
observed in other GPIIb/IIIa studies (4 – 6,12,13). It
should be noted that the CAPTURE, PRISM-PLUS and
PURSUIT trials employed concomitant high-dose heparin
(6,12,13), whereas heparin was given at a low dose both
before and during PCI in this study. This difference could
partly explain the relatively higher bleeding rates observed in
the PRISM-PLUS and PURSUIT trials (12,13). The rate
of thrombocytopenia (,100,000 platelets/ml) in our study
was also relatively low—only one of the 35 patients who
received combination therapy (2.9%).
Study limitations. The main limitation of this study was
the relatively small sample sizes, especially for clinical safety
assessment. In addition, patients were not randomly or
blindly assigned to one of the three treatment groups
although they were enrolled in a consecutive manner. Other
limitations are the use of venous blood in samples 1, 2, 5 and
6 and arterial blood in samples 3 and 4 and the use of two
different anticoagulants, which precluded comparison of the
relative effects of tirofiban and eptifibatide on platelet
function.
In conclusion, administration of abciximab immediately
after tirofiban or eptifibatide effectively inhibits platelet
function. Using concomitant low-dose heparin, this sequen-
tial GPIIb/IIIa regimen also appears to be safe although
further clinical assessment is required. These findings may
have important implications for patients with ACS treated
with a short-acting GPIIb/IIIa inhibitor in the early phase
of their clinical course. These patients may later require PCI
and could benefit from treatment with abciximab, for which
clear long-term benefits have been reported (9–11). Our
short overlap strategy allows them to receive abciximab
without a GPIIb/IIIa free interval, which may be hazardous
in ACS.
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